|
1
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Claes A, Idema AJ and Wesseling P: Diffuse
glioma growth: A guerilla war. Acta Neuropathol. 114:443–458. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups, : National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith TM, Lee MK, Szabo CI, Jerome N,
McEuen M, Taylor M, Hood L and King MC: Complete genomic sequence
and analysis of 117 kb of human DNA containing the gene BRCA1.
Genome Res. 6:1029–1049. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y and Jiang T: Understanding high
grade glioma: Molecular mechanism, therapy and comprehensive
management. Cancer Lett. 331:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eiden LE, Schäfer MK, Weihe E and Schütz
B: The vesicular amine transporter family (SLC18): Amine/proton
antiporters required for vesicular accumulation and regulated
exocytotic secretion of monoamines and acetylcholine. Pflugers
Arch. 447:636–640. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Linial M and Levius O: VAT-1 from
Torpedo is a membranous homologue of zeta crystallin. FEBS
Lett. 315:91–94. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Linial M, Miller K and Scheller RH: VAT-1:
An abundant membrane protein from Torpedo cholinergic
synaptic vesicles. Neuron. 2:1265–1273. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miki Y, Swensen J, Shattuck-Eidens D,
Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM,
Ding W, et al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koch J, Foekens J, Timmermans M, Fink W,
Wirzbach A, Kramer MD and Schaefer BM: Human VAT-1: A
calcium-regulated activation marker of human epithelial cells. Arch
Dermatol Res. 295:203–210. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vicanová J, Boelsma E, Mommaas AM,
Kempenaar JA, Forslind B, Pallon J, Egelrud T, Koerten HK and Ponec
M: Normalization of epidermal calcium distribution profile in
reconstructed human epidermis is related to improvement of terminal
differentiation and stratum corneum barrier formation. J Invest
Dermatol. 111:97–106. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Owens DW, Brunton VG, Parkinson EK and
Frame MC: E-cadherin at the cell periphery is a determinant of
keratinocyte differentiation in vitro. Biochem Biophys Res Commun.
269:369–376. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mori F, Tanigawa K, Endo K, Minamiguchi K,
Abe M, Yamada S and Miyoshi K: VAT-1 is a novel pathogenic factor
of progressive benign prostatic hyperplasia. Prostate.
71:1579–1586. 2011.PubMed/NCBI
|
|
16
|
Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad
M, Sepehrizadeh Z, Roshandel G, Ebrahimifard F and Setayesh N: Gene
expression profiling revealed overexpression of vesicle amine
transport protein-1 (VAT-1) as a potential oncogene in gastric
cancer. Indian J Biotechnol. 15:161–165. 2016.
|
|
17
|
Mertsch S, Becker M, Lichota A, Paulus W
and Senner V: Vesicle amine transport protein-1 (VAT-1) is
upregulated in glioblastomas and promotes migration. Neuropathol
Appl Neurobiol. 35:342–352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Novakova J, Slaby O, Vyzula R and Michalek
J: MicroRNA involvement in glioblastoma pathogenesis. Biochem
Biophys Res Commun. 386:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palumbo S, Miracco C, Pirtoli L and
Comincini S: Emerging roles of microRNA in modulating cell-death
processes in malignant glioma. J Cell Physiol. 229:277–286. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao X and Jin W: The emerging role of
tumor-suppressive microRNA-218 in targeting glioblastoma stemness.
Cancer Lett. 353:25–31. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y, Ding L, Hu Q, Xia J, Sun J, Wang
X, Xiong H, Gurbani D, Li L, Liu Y, et al: MicroRNA-218 functions
as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and
negatively correlates with poor prognosis. Mol Cancer. 16:1412017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu J, Wang Y, Dong R, Huang X, Ding S and
Qiu H: Circulating microRNA-218 was reduced in cervical cancer and
correlated with tumor invasion. J Cancer Res Clin Oncol.
138:671–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gu J, Xu R, Li Y, Zhang J and Wang S:
MicroRNA-218 modulates activities of glioma cells by targeting
HMGB1. Am J Transl Res. 8:3780–3790. 2016.PubMed/NCBI
|
|
27
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fecci PE, Ochiai H, Mitchell DA, Grossi
PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD and
Sampson JH: Systemic CTLA-4 blockade ameliorates glioma-induced
changes to the CD4+ T cell compartment without affecting
regulatory T-cell function. Clin Cancer Res. 13:2158–2167. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
See AP, Parker JJ and Waziri A: The role
of regulatory T cells and microglia in glioblastoma-associated
immunosuppression. J Neurooncol. 123:405–412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shukla SA, Rooney MS, Rajasagi M, Tiao G,
Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman
S, et al: Comprehensive analysis of cancer-associated somatic
mutations in class I HLA genes. Nat Biotechnol. 33:1152–1158. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Doucette T, Rao G, Rao A, Shen L, Aldape
K, Wei J, Dziurzynski K, Gilbert M and Heimberger AB: Immune
heterogeneity of glioblastoma subtypes: Extrapolation from the
cancer genome atlas. Cancer Immunol Res. 1:112–122. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Supper V, Hartl I, Boulègue C,
Ohradanova-Repic A and Stockinger H: Dynamic interaction- and
phospho-proteomics reveal Lck as a major signaling hub of CD147 in
T cells. J Immunol. 198:2468–2478. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arreola R, Alvarez-Herrera S,
Pérez-Sánchez G, Becerril-Villanueva E, Cruz-Fuentes C,
Flores-Gutierrez EO, Garcés-Alvarez ME, de la Cruz-Aguilera DL,
Medina-Rivero E, Hurtado-Alvarado G, et al: Immunomodulatory
effects mediated by dopamine. J Immunol Res. 2016:31604862016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Essand M, Vikman S, Grawé J, Gedda L,
Hellberg C, Oberg K, Totterman TH and Giandomenico V:
Identification and characterization of a novel splicing variant of
vesicular monoamine transporter 1. J Mol Endocrinol. 35:489–501.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wimalasena K: Vesicular monoamine
transporters: Structure- function, pharmacology, and medicinal
chemistry. Med Res Rev. 31:483–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cosentino M, Fietta AM, Ferrari M, Rasini
E, Bombelli R, Carcano E, Saporiti F, Meloni F, Marino F and
Lecchini S: Human CD4+CD25+ regulatory T
cells selectively express tyrosine hydroxylase and contain
endogenous catecholamines subserving an autocrine/paracrine
inhibitory functional loop. Blood. 109:632–642. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amenta F, El-Assouad D, Mignini F, Ricci A
and Tayebati SK: Neurotransmitter receptor expression by peripheral
mononuclear cells: Possible marker of neuronal damage by exposure
to radiations. Cell Mol Biol (Noisy-le-grand). 48:415–421.
2002.PubMed/NCBI
|
|
38
|
Musso NR, Brenci S, Setti M, Indiveri F
and Lotti G: Catecholamine content and in vitro catecholamine
synthesis in peripheral human lymphocytes. J Clin Endocrinol Metab.
81:3553–3557. 1996. View Article : Google Scholar : PubMed/NCBI
|
